Nuvation Bio IncNYSE:NUVB
- LAST PRICE2.9400
- TODAY'S CHANGE (%)-0.0800 (-2.6490%)
- Bid / Lots2.9300/ 25
- Ask / Lots2.9400/ 22
- Open / Previous Close3.0100 / 3.0200
- Day Range
- 52 Week Range
- Volume282,222
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NUVB |
|---|---|---|
| 09:32 ET | 14736 | 2.97 |
| 09:34 ET | 8129 | 3.02 |
| 09:36 ET | 6093 | 3 |
| 09:38 ET | 3100 | 3 |
| 09:39 ET | 5929 | 3.02 |
| 09:41 ET | 8602 | 3.01 |
| 09:43 ET | 2550 | 2.995 |
| 09:45 ET | 6641 | 3.03 |
| 09:48 ET | 5691 | 3.02 |
| 09:50 ET | 2748 | 3.02 |
| 09:52 ET | 2396 | 3.02 |
| 09:54 ET | 2948 | 3.03 |
| 09:56 ET | 600 | 3.03 |
| 09:57 ET | 3229 | 3.03 |
| 09:59 ET | 1400 | 3.03 |
| 10:01 ET | 3899 | 3.02 |
| 10:03 ET | 3345 | 3.03 |
| 10:06 ET | 10902 | 3.025 |
| 10:08 ET | 300 | 3.03 |
| 10:10 ET | 7312 | 3.005 |
| 10:12 ET | 2454 | 2.99 |
| 10:14 ET | 1132 | 2.985 |
| 10:15 ET | 2531 | 3 |
| 10:17 ET | 400 | 2.9999 |
| 10:19 ET | 5244 | 3.01 |
| 10:21 ET | 900 | 3.01 |
| 10:24 ET | 1000 | 3.01 |
| 10:26 ET | 1000 | 3.01 |
| 10:28 ET | 10701 | 2.985 |
| 10:30 ET | 3248 | 2.975 |
| 10:32 ET | 300 | 2.98 |
| 10:33 ET | 9499 | 2.985 |
| 10:35 ET | 4251 | 2.99 |
| 10:37 ET | 2868 | 3 |
| 10:39 ET | 3193 | 3.01 |
| 10:42 ET | 4469 | 3 |
| 10:44 ET | 2700 | 2.985 |
| 10:46 ET | 900 | 2.985 |
| 10:48 ET | 14307 | 2.98 |
| 10:50 ET | 1324 | 2.975 |
| 10:51 ET | 8803 | 2.965 |
| 10:53 ET | 200 | 2.97 |
| 10:55 ET | 3099 | 2.975 |
| 10:57 ET | 500 | 2.98 |
| 11:00 ET | 700 | 2.98 |
| 11:02 ET | 3311 | 2.99 |
| 11:04 ET | 100 | 2.99 |
| 11:06 ET | 7019 | 2.96 |
| 11:08 ET | 6696 | 2.955 |
| 11:09 ET | 500 | 2.955 |
| 11:11 ET | 4467 | 2.965 |
| 11:13 ET | 400 | 2.965 |
| 11:15 ET | 754 | 2.965 |
| 11:18 ET | 600 | 2.97 |
| 11:20 ET | 8527 | 2.965 |
| 11:22 ET | 100 | 2.97 |
| 11:24 ET | 406 | 2.965 |
| 11:26 ET | 500 | 2.97 |
| 11:27 ET | 1860 | 2.965 |
| 11:29 ET | 3318 | 2.98 |
| 11:31 ET | 300 | 2.97 |
| 11:33 ET | 5343 | 2.97 |
| 11:36 ET | 4273 | 2.96 |
| 11:38 ET | 8847 | 2.945 |
| 11:40 ET | 3294 | 2.94 |
| 11:42 ET | 300 | 2.935 |
| 11:44 ET | 200 | 2.935 |
| 11:45 ET | 500 | 2.94 |
| 11:47 ET | 1400 | 2.94 |
Jun 3, 2024
DJ Nuvation Bio Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 6:46AM ET on Monday Jun 03, 2024 by Dow Jones
6:46AM ET on Monday Jun 03, 2024 by Dow Jones
Jun 1, 2024
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting, from 8:10AM ET on Saturday Jun 01, 2024 by Dow Jones
8:10AM ET on Saturday Jun 01, 2024 by Dow Jones
May 29, 2024
Nuvation Bio to Present at the Jefferies Global Healthcare Conference, from 4:05PM ET on Wednesday May 29, 2024 by Dow Jones
4:05PM ET on Wednesday May 29, 2024 by Dow Jones
May 24, 2024
DJ Nuvation Bio Price Target Maintained With a $5.00/Share by Wedbush, from 10:02AM ET on Friday May 24, 2024 by Dow Jones
10:02AM ET on Friday May 24, 2024 by Dow Jones
May 22, 2024
DJ Nuvation Bio Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 6:42AM ET on Wednesday May 22, 2024 by Dow Jones
6:42AM ET on Wednesday May 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nuvation Bio Inc | 746.5M | -9.3x | --- |
Hillevax Inc | 750.3M | -4.6x | --- |
Scholar Rock Holding Corp | 753.7M | -4.3x | --- |
Mereo BioPharma Group PLC | 596.2M | -16.6x | --- |
CARGO Therapeutics Inc | 766.6M | -5.2x | --- |
Longboard Pharmaceuticals Inc | 720.1M | -8.2x | --- |
Company Information
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Contact Information
- Headquarters
- 357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103
- Phone
- 415-754-3517
- Fax
- 302-636-5454
Executives
- Independent Chair of the Board
- Daniel Welch
- President, Chief Executive Officer, Founder, Director
- David Hung
- Principal Financial and Accounting Officer, Vice President - Finance
- Moses Makunje
- Chief Executive Officer of AnHeart Therapeutics and Director
- Junyuan Wang
- Chief People Officer
- Stacy Markel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $746.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
